With SET7′s emerging role of therapy targets for cancers, diabetes, hepatocellular carcinoma, alopecia areata, pulmonary fibrosis and viral infections, a potent and selective SET7 inhibitor is in great need to serve as a chemical probe to investigate its delicate biological function and mechanism. This evidence concerns the gene SETD7 and alopecia areata.